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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
This review aims to assess the effectiveness of interventions including a service brokerage component for people transitioning out of
prison, on health outcomes post-release.
B A C K G R O U N D
Description of the condition
More than 10 million adults are currently incarcerated around the
world with more than one in five of these held in jails or prisons
(hereafter collectively described as ’prisons’) in the US. Although
the US has the highest per capita incarceration rate in the world,
prison populations in most countries are increasing (Walmsley
2011) and due to the preponderance of short sentences, the num-
ber of people moving in and out of prison is considerably larger,
with more than 30 million people estimated to move through
prison systems worldwide each year (UNODC 2008). High rates
of recidivism (Gendreau 1996) and mortality (Binswanger 2007;
Kariminia 2007; Merrall 2010) post-release indicate that integra-
tion of ex-prisoners into the community is often unsuccessful.
Ex-prisoners are characterised by chronic social disadvantage, poor
physical and mental health, and high rates of substance misuse
- a continuation of problems experienced prior to imprisonment
(Kinner 2006). In many countries the prevalence of infectious dis-
eases including human immunodeficiency virus (HIV), tuberculo-
sis, hepatitis C and sexually transmitted infection (STI) are greatly
elevated among prisoners (Butler 2011; David 2003; Hammett
2002; Jürgens 2009; Macalino 2004; Seal 2003); as is the preva-
lence of mental illness and alcohol and other drug problems, par-
ticularly injecting drug use (Fazel 2006; Fazel 2002). Consistent
with this, ex-prisoners die at rates that are orders of magnitude
higher than their community peers, especially in the first fewweeks
after release, and often due to drug overdose or suicide (Kariminia
2007; Kinner 2011; Merrall 2010). Time in prison may com-
pound existing problems through the accumulation of debt, loss of
housing, isolation from family and friends, and time without ac-
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cumulation of work experience and referees (Baldry 2003; Visher
2003). Many prisoners return to the community ill-equipped to
deal with their often complex health and psychosocial needs. Al-
though the majority of the world’s prisoners are in developing
countries, most studies of ex-prisoners take place in developed
countries; it remains unclear to what extent the existing evidence
can be extrapolated to resource-poor settings (Kinner 2012).
There is growing evidence to suggest that while poor health and
psychosocial outcomes for ex-prisoners represent a significant pub-
lic health issue in their own right, they are also associated with
re-offending (Dowden 2002; Hobbs 2006). This relationship is
poorly understood, and it is unknown whether a causal relation-
ship between health and justice outcomes exists (i.e. poor health
leads to re-offending), or the circumstances associated with poor
health overlap with those associated with re-offending (i.e. inter-
mediate mechanisms lead to both poor health and re-offending).
In either case, the mechanisms underpinning recidivism and poor
health (such as homelessness, unemployment, illicit drug use, poor
social support, under-utilisation of healthcare) are important to
understanding post-release outcomes. Given the well-documented
links between poor health, health risk behaviours and offending,
improving health outcomes for ex-prisoners is important from
both public health and criminal justice perspectives.
Description of the intervention
Transitional interventions for prisoners usually fall into one of
three categories: (1) interventions delivered pre-release, (2) inter-
ventions delivered post-release or (3) interventions that involve
both pre-release and post-release components. While some inter-
ventions have an explicit focus on health or health-related be-
haviours, others are designed primarily to reduce re-offending.
For example, Project Greenlight (Wilson 2006) was a quasi-ran-
domised trial of an intervention delivered to a sample of prisoners
in New York State, US, in the eight weeks before their release from
custody. The intervention included a cognitive skills component
to address antisocial behaviours and thinking; relapse prevention
and practical living skills; preparation for accessing community
services; identification of relevant community organisations and
preparation of a detailed release plan. Although the primary aim
of the intervention was to reduce recidivism, it included a focus
on substance use, living skills and community engagement, and
measured a range of health and psychosocial outcomes includ-
ing substance use, family relationships and service access. Simi-
larly, the multi-site Serious and Violent Offender Reentry Initia-
tive (SVORI) was designed to reduce recidivism but also sought
to improve employment, housing and health outcomes through
improved access to services (Lattimore 2009). In this intervention,
community agencies were funded to provide needs-based and co-
ordinated support, starting prior to release and continuing for a
period of time post-release. By contrast, Project START, another
multi-site transitional intervention in the US, was designed pri-
marily to reduce sexual risk behaviour in youngmen being released
fromprison, although recidivismwasmeasured as a secondary out-
come (Wolitski 2006). This intervention incorporated prevention
case management, motivational interviewing and harm reduction,
and comprised two pre-release and four post-release sessions. One
common feature of these interventions is that they sought to im-
prove outcomes for ex-prisoners through, among other things, fa-
cilitating access to services in the community post-release. It is
this sort of transitional intervention, hereafter described as ’service
brokerage’, which is the focus of this review.
How the intervention might work
Although many transitional interventions aim to reduce recidi-
vism, theymay include a focus on health or health risk behaviours,
or both, as hypothesised mechanisms of change, based on the
assumption that reduced re-offending can be achieved through
improved health, reduced health risk behaviour and better psy-
chosocial adjustment. Thus, many transitional interventions aim
to maintain or improve health (e.g. reduced incidence of HIV
infection, improved mental health), reduce risk behaviour (e.g.
injecting drug use, unsafe sex), promote social integration (e.g.
employment, sustained relationships) or a combination of these.
Rather than targeting these outcomes directly, service brokerage
interventions aim to achieve these outcomes through improved
access to (and utilisation of ) relevant health and community ser-
vices, after release from custody. An advantage of such interven-
tions is that they do not duplicate existing community resources
or, compared with dedicated services for ’ex-prisoners’, risk per-
petuating stigma by framing service recipients as ’offenders’ rather
than members of the community.
Why it is important to do this review
Internationally, although a number of interventions designed to
improve health outcomes for ex-prisoners have been the sub-
ject of evaluation (e.g. Callan 2001; Inciardi 2004; Knight 1999;
Prendergast 2004), the evidence base remains weak and these eval-
uations have never been considered together as a body of evidence.
This limited evidence base contrasts with a large literature exam-
ining interventions designed to reduce recidivism in ex-prisoners
(the ’what works’ literature), which has been the subject of several
meta-analyses (e.g. Bonta 1998; Dowden 2002; Gendreau 1996).
Currently, given the limited evidence base, it is difficult to state
with confidence whether, and importantly how, health outcomes
for ex-prisoners can be improved. Randomised controlled trials
(RCTs) are rare, and many studies are compromised by the use of
small convenience samples, exclusive reliance on self-report or ad-
ministrative data and poor generalisability. Other evaluation stud-
ies, particularly of therapeutic communities, often suffer from se-
lection bias and a consequent lack of representativeness. In ad-
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dition to these methodological considerations, generalisation of
study findings to an international context is problematic, due to
important differences in correctional environments, policies and
practices, the quality and accessibility of community health ser-
vices, patterns of substance use and the distribution of disease.
Given growing evidence that some widely adopted interventions
can actually produce harmful outcomes for ex-prisoners (Petrosino
2002;Wilson 2006), it is insufficient to assume that well-meaning
interventions will have either no effect, or a positive effect. Re-
searchers and practitioners alike must “first do no harm” (Wilson
2007).
Given that the literature on improving health outcomes for ex-
prisoners has never before been subjected to systematic review,
it is also unclear what knowledge gaps exist, and thus how re-
searchers can maximise their impact by prioritising and targeting
future research. Critical review of the literature from a method-
ological perspective will also arm research consumers with appro-
priate caveats, as they consider the evidence for ’what works’ to
improve the health of ex-prisoners.
Finally, although a number of studies have included comparisons
or stratified analyses by gender, age, minority group status, or
a combination of these, these differences have rarely been high-
lighted by the authors, and subgroup differences have never been
considered across studies or contexts. This is a significant omis-
sion, given evidence that these groups may have unique strengths,
needs and post-release experiences.
This review will address the issues highlighted above by systemat-
ically reviewing the evidence for interventions that target people
transitioning out of prison and include a service brokerage com-
ponent. Although the extant literature includes many studies and
a number of meta-analyses of interventions to reduce recidivism,
this review will address a major research gap by identifying health
as the primary outcome measure. To ensure that the review con-
siders the impact of service brokerage interventions on justice out-
comes, recidivism will be included as a secondary outcome.
O B J E C T I V E S
This review aims to assess the effectiveness of interventions includ-
ing a service brokerage component for people transitioning out of
prison, on health outcomes post-release.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs, cluster RCTs, quasi-RCTs, controlled be-
fore-and-after studies (where intervention and outcome measure-
ments are contemporaneous) and interrupted time series studies.
Interrupted time series must have a clearly identifiable time point
at which the intervention occurred and must include measure-
ments for at least three time points before and after the interven-
tion. Studies where groups are allocated must have at least two
groups in each arm of the study. Our reasons for including non-
RCT designs are that (a) ethical considerations sometimes neces-
sitate other study designs and (b) interventions in this area are
usually delivered by mandated service providers rather than re-
searchers, such that the evaluation design must align with service
provision requirements. Process evaluations associated with the
included studies (including qualitative data) will be included to
provide context for the findings (Popay 2006).
Types of participants
Participants will be adult and juvenile ex-prisoners. For the pur-
poses of this review, ex-prisoners are defined as people who have
spent a period of time held against their will in a juvenile or adult
prison (or jail) (including pre-trial detention) and who have been
released from a juvenile or adult prison (or jail) into the commu-
nity, without any limits being ascribed to length of time served
in custody. Individuals held against their will in psychiatric facili-
ties or other primarily therapeutic contexts will be excluded from
this definition. People released intohospitals, includingpsychiatric
hospitals, will also be excluded from this definition. Individuals
held against their will in other punitive environments, such as the
06 ’compulsory drug rehabilitation’ centres in Vietnam (Jürgens
2010) will be included if suitable studies are found.
There will be no limits on geographic location; this review will
consider international studies, including studies from developing
countries, if available.
Types of interventions
Included interventions will be those that include a component
designed to facilitate access to or utilisation of health or psychoso-
cial services (or both) in the community, including, for example,
housing or employment services. Examples of eligible interven-
tions include (a) providing prisoners or ex-prisoners with writ-
ten information about community-based services, (b) ’in-reach’
whereby community services visit prisons and engage with prison-
ers prior to release, and (c) ’case management’ whereby a worker
in a prison or community setting assists a prisoner/ex-prisoner to
access community services by making appointments on their be-
half or accompanying them to such services. Interventions may
have multiple components, including direct service provision, but
must include a service brokerage component. Interventions may
include direct or indirect financial incentives or subsidies to in-
crease the affordability of services, but interventions with no such
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incentive or subsidy will also be included. Interventions delivered
in prison, those delivered post-release, and those with both pre-
release and post-release components will be included.
The control/comparator intervention is ’usual care’, which may
vary between studies. Heterogeneity of the comparator groups will
be considered during the review. There will be no restrictions on
dose, frequency, intensity or durationof the intervention, although
these variables will be considered in specific comparisons.
Types of outcome measures
The focus of this review will be health outcomes so, to be included,
studies must report on one or more health-related outcomes, even
if these are not the primary focus of the study. Specifically, our
primary outcome measures are substance use (a key predictor of
both poor health outcomes and recidivism in this population)
and health-related quality of life. Secondary outcomes will include
health, health service utilisation and recidivism. Qualitative data
obtained from process evaluations associated with the included
studies and information on cost/resource requirements of the in-
tervention will be collected to provide context for the findings.
For the purposes of this review, we adopt theWorld Health Orga-
nization (WHO) definition of health: “...a state of complete physi-
cal, mental and social well-being and not merely the absence of disease
or infirmity” (WHO 1948). With this definition in mind, our sec-
ondary health outcomes fall into three broad categories: physical
health, mental health and health risk behaviours. To explore the
links between health and offending behaviour, we include recidi-
vism as a secondary outcome.
Although we anticipate considerable heterogeneity in outcome
measures, under each of the sub-categories below we will select
the most frequently reported outcome measure to represent that
outcome sub-category in data synthesis. Where the same under-
lying construct is measured using multiple measures (e.g. health-
related quality of life measured by the short form-36 (SF-36) and
Symptom Checklist-90 (SCL-90)), we will treat these measures as
comparable for the purposes of taking a median effect size.
Where one study provides data on multiple outcomes, each out-
come will be considered in the appropriate analysis. Where out-
comes are measured at multiple time points, the time point that is
measured immediately post-intervention will be the primary mea-
sure since this will be most commonly measured in other studies
and therefore expected to be the most comparable. Subsequent
time points will be considered in assessing the sustainability of
interventions. We will consider time points during or within three
months of cessation of the intervention to be short-term; time
points four to 12 months post-intervention will be considered
medium-term, and time points > 12 months’ post-intervention
will be considered long-term.
Primary outcomes
1. Health-related quality of life (as measured by self-report
instruments such as the SF-36, SCL-90, General Health
Questionnaire (GHQ)).
2. Substance use (as measured by self-report instruments such
as the Opiate Treatment Index, AUDIT or WHO ASSIST; or by
objective measures such as urinalysis).
Secondary outcomes
1. Health service utilisation: initiation, engagement and
retention (e.g. incidence of vaccination; count of people or
occasions of service utilisation, by service type):
i) medication adherence.
2. Physical health. Important sub-categories and examples of
specific outcomes include:
i) chronic physical health conditions (e.g. incidence of
HIV, hepatitis C, STIs; diabetes; cardiovascular disease; cancer);
ii) acute physical health conditions (e.g. incidence of
acute respiratory infection, non-fatal drug overdose, injury);
iii) mortality (all-cause, drug-related, suicide).
3. Mental health. Important sub-categories and examples of
specific outcomes include:
i) anxiety disorders (e.g. post-traumatic stress disorder
(PTSD), generalised anxiety disorder) and mood disorders (e.g.
depression, bipolar disorder);
ii) substance disorders (abuse, dependence; by drug type);
iii) psychotic disorders (e.g. drug-induced psychosis).
4. Sexual risk behaviour (e.g. unprotected sex, multiple sex
partners).
5. Recidivism (measured as re-offending, re-arrest, re-
incarceration within a specified time period, or a combination of
these; by self-report or official records).
6. Any unexpected adverse outcome.
Search methods for identification of studies
In order to minimise publication bias, we will attempt to identify
both published and unpublished studies, with no language or date
restrictions. If we identify articles written in a language other than
English we will attempt to obtain full translations. These will be
stored in the awaiting assessment section of the review until a
translation is obtained. We will also seek to minimise discipline
bias by searching databases in the fields of health, social science
and criminology.
Electronic searches
We will search the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL);
• International Initiative for Impact Evaluation (3ie)
database;
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• British Nursing Index;
• CINAHL;
• CINCH (Australian Institute of Criminology database);
• Criminal Justice Abstracts;
• Dissertation Abstracts;
• EMBASE;
• EPPI-Centre BiblioMap and TRoPHI;
• Health Management Information Consortium (HMIC)
Database;
• MEDLINE and MEDLINE In-Process;
• National Criminal Justice Reference Service (NCJRS)
abstracts [US Department of Justice];
• Open System for Information on Grey Literature in Europe
(OpenGrey);
• ProQuest Social Science Abstracts;
• PsycINFO;
• Sage Full Text collections (Criminology, Sociology);
• Social Services Abstracts;
• Sociological Abstracts;
• SCOPUS;
• Web of Science Social Sciences Citation Index (SSCI) and
Science Citation Index (SCI);
• World Health Organization WHOLIS database;
• Many publishers (e.g. Wiley) now have search functions on
their websites.
We will also search the Cochrane Public Health Group (CPHG)
Specialised Register and the Effective Practice and Organisation
of Care (EPOC) Group Specialised Register, and the Campbell
Collaboration Social, Psychological, Educational & Criminolog-
ical Trials Register (C2-SPECTR) bibliography for studies pub-
lished in 2003 or earlier.
For all electronic searches, the following outline of a search strat-
egy for PubMed will be tailored for each database. Given that rela-
tively few studies have examined health outcomes in ex-prisoners,
that interventions may be intended primarily to reduce recidivism
(rather than improve health), and that there is no consensus in
the literature regarding appropriate terminology to describe ser-
vice brokerage interventions for this population, the search will
not be filtered by intervention terms. Similarly, given that some
studies may report health outcomes only incidentally, the search
will initially identify studies based on health or recidivism out-
comes, although studies that do not report at least one health-
related outcome will subsequently be excluded.
PubMed population terms
1. “*prison*”
2. “*offend*”
3. “remand*”
4. “*detain*”
5. “*criminal*”
6. “*convict*”
7. “*felon*”
8. “(pre- OR under-) trial”
9. “jail”
10. “gaol”
11. “detention”
12. “correction*”
13. “sentence*”
14. “probation*”
15. “parole*”
16. “re-entry OR reentry”
17. “post-release”
18. “transition*”
19. “supervis*”
20. or/1-19
PubMed health and recidivism outcome terms
21. “health”
22. “physical health”
23. “general health”
24. “mental health”
25. “illness”
26. “disorder”
27. “well-being”
28. “quality of life”
29. “[drug OR alcohol OR substance] AND [use OR abuse OR
misuse OR dependence]”
30. “addict*”
31. “inject*”
32. “overdose”
33. “[unsafe OR risky OR unprotected] AND [sex OR inter-
course]”
34. “HIV”
35. “AIDS”
36. “[STI OR STD]”
37. “[sexually transmitted] AND [illness OR infection OR dis-
ease]”
38. “service AND [contact OR utilisation OR utilization]”
39. “contact with services”
40. “doctor”
41. “primary care”
42. “general practitioner”
43. “treatment”
44. “recidiv*”
45. “reoffend*”
46. “reincarcerat*”
47. “*arrest*”
48. “*convict*”
49. “violat*”
50. “revoke*”
51. “revocation”
52. “breach”
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53. or/21-52
PubMed design terms (filter)
54. “randomised controlled trial”
55. “controlled clinical trial”
56. “controlled trial”
57. “clinical trial”
58. “random*”[Title/Abstract]
59. “controlled”[Title]
60. “control* AND (clinical OR group* OR trial* OR study OR
studies OR design* or method*)”[Title/Abstract]
61. “control group*”
62. “single-blind method”
63. “double-blind method”
64. “RCT”
65. “*intervention*”[Title/Abstract]
66. “evaluation”[Title/Abstract]
67. “pre-testORpretestORpost-testORposttest”[Title/Abstract]
68. “control* AND (before OR after)”[Title/Abstract]
69. “quasi-experiment* OR quasi-random* OR quasi-con-
trol*”[Title\Abstract]
70. “(quasi* OR experimental) AND (method* or study OR stud-
ies OR trial OR design*)”[Title/Abstract]
71. “time series”
72. “(multicent* OR multi-cent*)” AND (stud* OR design OR
trial)“[Title/Abstract]
73. ”(case control OR case-control) AND (design* or stud* or
trial*)“[Title/Abstract]
74. ”follow up OR follow-up“
75. ”(crossover OR cross-over) AND (design* OR stud* OR
trial*)“[Title/Abstract]
76. ”pilot AND (project* or stud*)“[Title/Abstract]
77. ”comparative stud*“[Title/Abstract]
78. ”comparison group“
79. ”intervention stud*“
80. ”program AND (effect* OR evaluat*)“[Title/Abstract]
81. ”evaluation“[Title[/Abstract]
82. or/54-81
Searching other resources
We will attempt to identify grey literature using keyword searches
in Google and Google Scholar, searches of government and
non-government websites (e.g. WHO, United Nations Office
on Drugs and Crime (UNODC), and Correctional Service of
Canada), and online clearinghouses such as the Lloyd Society’s Jus-
tice Health Library (thelloydsociety.org/work/current_projects/
jhl/) and the Offender Health section of the Australian In-
digenous Health Clearinghouse (www.healthinfonet.ecu.edu.au/
population-groups/offender-health).
We will search the international clinical trials registry platform
(ICTRP) and the ANZ Clinical Trials Registry (ANZCTR) to
identify ongoing or planned studies. Potential studies will also
be identified through consultation with Review Advisory Group
(RAG) members.
We will also handsearch the reference lists of included studies and
other relevant papers and handsearch key journals for the past
12 months to identify studies that may not yet be indexed in
databases.
Data collection and analysis
Selection of studies
All potential studies identified from the searches will be down-
loaded into reference management software and duplicates re-
moved. The titles and abstracts of identified studies will be
screened independently by two review authors to determine eligi-
bility according to the inclusion and exclusion criteria listed above.
Full copies of all eligible papers will be retrieved. When a title or
abstract cannot be rejected with certainty, the full text of the article
will be obtained for further evaluation. If there is disagreement
between the two review authors at any stage, this will be resolved
by discussion, and if necessary, consultation with a third review
author. Multiple reports related to the same study will be linked
together. Studies that appear to be relevant but do not meet the
inclusion criteria will be listed in the table of excluded studies with
reasons given for exclusion.
Data extraction and management
Data will be extracted independently by two review authors us-
ing a data extraction form based on the template provided by the
Cochrane Public Health Group. Any disagreements will be re-
solved by discussion and, if necessary, consultation with a third
review author. Study information to be extracted, where available,
will include:
• year of publication;
• country of origin;
• study design;
• sample size;
• recruitment details;
• sample description (i.e. gender, age, ethnicity);
• theoretical basis for intervention;
• intervention type (i.e. pre-release only, throughcare, or
post-release only; manualised or tailored);
• delivery of intervention;
• direct resource/cost requirements of the intervention;
• duration of intervention and follow-up;
• intensity of intervention;
• outcomes (including scales/measures used, time points and
results);
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• whether or not adverse outcomes were measured and
reported;
• potential moderators/confounders of study outcomes and
any adjustment processes used;
• population characteristics in terms of the factors outlined
by PROGRESS-Plus (Place, Race, Occupation, Gender,
Religion, Education, SES [socioeconomic status], Social capital
PLUS disability, sexual orientation), as well as analyses of
outcomes by any of these factors;
• process evaluation measures;
• presence and extent of any bias in attrition.
Data from multiple reports of the same study will be collated
into one data extraction form pertaining to the study. Data will
be entered into Review Manager (RevMan 2011) software and
checked for accuracy.
Assessment of risk of bias in included studies
Risk of bias of included studies, with the exception of interrupted
time series, will be assessed using the Cochrane EPOC (Effective
Practice and Organisation of Care) ’Risk of bias’ tool for studies
with a separate control group. This includes the assessment of se-
quence generation; allocation concealment; confounding; incom-
plete outcome data; blinding of participants, personnel and out-
come assessors; contamination; selective outcome reporting and
other sources of bias.
Risk of bias for interrupted time series designs will be assessed
using the Cochrane EPOC ’Risk of bias’ tool for such designs.
This includes the assessment of whether the intervention was in-
dependent of other changes, unlikely to affect data collection; and
whether the shape of the intervention effect was pre-specified. Also
included is the assessment of blinding of participants, personnel
and outcome assessors; incomplete outcome data; selective out-
come reporting and other sources of bias.
Risk of bias will be assessed independently by two review authors
and any discrepancieswill be resolved by discussionor consultation
with a third review author if necessary.
Overall risk of bias
For all included studies, the overall risk of bias will be summarised
at the outcome level within each study. This is the recommended
level at which to summarise ’Risk of bias’ assessments, since some
risks of bias may be different for different outcomes within the
same study (Higgins 2011). This summary assessment will take
into account domains that are at the study level, such as adequate
sequence generation, as well as those at the outcome level, such as
blinding. Judgements about overall risk of bias will also take into
account the likely magnitude and direction of bias and whether it
is likely to impact on the findings of the study. The overall risk of
bias will then be summarised at the outcome level across studies
reporting similar outcomes taking into account the proportion of
information from studies at low, high and unclear risk of bias. The
impact of including studies at high risk of bias will be explored
using a sensitivity analysis. For the purposes of this analysis, studies
at ’high risk’ of bias will be those assessed as having a high risk of
bias with respect to sequence generation or confounding, or both.
Measures of treatment effect
Dichotomous outcomes will be reported as mean risk ratios (RR)
with 95% confidence intervals (CI). Continuous outcomes will be
presented as the difference inmean values with 95%CIs. If studies
use different measures for the same outcome, we will use standard-
ised mean difference (SMD) as a relative measure for continuous
outcomes, where appropriate. No re-calculations of means will be
performed; however, if standard deviations are not reported, they
will be derived from the reported standard error of the mean, or
95% CIs using the equations provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).Ordinal out-
come measures may be analysed as either dichotomous or con-
tinuous data and reported in the corresponding format described
above. Where possible, based on reporting and analysis in primary
studies, effect sizes derived from interrupted time series designs
will be reported as the change in the level of outcome at the first
measurement point after the introduction of the intervention or
the change in the slopes of the regression lines (post-intervention
minus pre-intervention slope), or both (Ramsay 2003). Either of
these effect sizes will be considered as evidence of intervention ef-
fect, if deemed significant. Qualitative process data will be used to
assess intervention intensity and provide context for the findings.
Unit of analysis issues
Cluster randomised trials
Studies that allocate or randomise clusters and conduct their anal-
ysis at a different level to that of allocation need to account for
clustering in their analysis to avoid potential unit of analysis er-
rors. For studies that do not report appropriately accounting for
clustering, we will contact the study authors to request missing
information and attempt to re-analyse the data using the method
outlined in the Cochrane Handbook for Systematic Reviews of In-
terventions. If this approach is used, we will mark the data as re-
analysed. If re-analysis is not possible, we will note all studies with
potential unit of analysis errors and discuss the implications for
precision of effect estimates.
Studies with more than two treatment groups
If we identify studies with more than two intervention groups
(multi-arm studies), where possible we will combine groups to
create a single pair-wise comparison or use the methods set out in
the Cochrane Handbook for Systematic Reviews of Interventions to
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avoid double-counting of study participants (Higgins 2011). For
subgroup analyses, where the control group is shared by two or
more study arms, we will divide the control group by the number
of relevant subgroups to avoid double-counting of participants.
Dealing with missing data
For missing summary data, we will contact study investigators
for clarification, or if possible, we will estimate missing summary
data using other information provided in the publication. We will
carry out analyses, as far as possible, on an intention-to-treat basis,
analysing participants in the group to which they were allocated
regardless of whether or not they received the allocated interven-
tion. It is also recognised that not all intervention group partici-
pants may receive the same ’dosage’ of intervention; accordingly,
we will conduct an intention-to-treat analysis wherever possible.
Assessment of heterogeneity
Heterogeneity will initially be considered in terms of meaning-
ful variation in the participants, interventions and outcomes mea-
sured in included studies, sometimes known as clinical hetero-
geneity. Methodological heterogeneity will also be considered in
terms of the variation in the study designs of included studies. If
meta-analyses are appropriate, we will conduct a visual assessment
of all forest plots and generate Chi2 and I2 statistics to quantify
the level of statistical heterogeneity, which may be a consequence
of clinical or methodological heterogeneity or both. We will not
combine results from different types of study designs together
in a meta-analysis. We expect considerable heterogeneity due to
the broad scope of this review, and we plan to group studies by
population, interventions and outcomes where it might be more
meaningful to do so, based on clinical heterogeneity. We also plan
to use a random-effects model for meta-analyses to incorporate
likely statistical heterogeneity. If we find that I2 < 30 (along with
a high P value from the Chi2 test), we will consider using a fixed-
effect model as the primary model. Depending on the number of
available studies, we will explore potential causes of heterogeneity,
based on the pre-specified subgroup analyses listed below. Caution
will be taken in the interpretation of results with a high level of
unexplained heterogeneity.
Assessment of reporting biases
If more than 10 studies are identified that report the same out-
come of interest, we will explore publication bias using funnel
plots to assess the relationship between effect size and study preci-
sion. If meta-analyses have been conducted and we are concerned
about small study effects, we will compare the fixed- and random-
effects estimate of the intervention effect in a sensitivity analysis
to identify the level of impact caused by different effect estimates
in small studies. A random-effects meta-analysis weights the stud-
ies more equally than a fixed-effect analysis, therefore in the case
where the intervention effect is more beneficial in smaller studies,
the random-effects estimate will be expected to be more beneficial
than the fixed-effect estimate (Poole 1999). If we find that there
is a large difference between the random-effects estimate and the
fixed-effect estimate, we will examine whether there are consis-
tent differences between the smaller and larger studies in risk of
bias, population or intervention (according to our pre-specified
groupings identified in the Data synthesis and Subgroup analysis
and investigation of heterogeneity sections) to determine possi-
ble causes and to decide on the most appropriate way to present
studies in meta-analyses. For example, if the larger studies were
generally assessed to be at a lower risk of bias and were conducted
in circumstances that reflect the more typical or appropriate use
of the intervention in practice, meta-analyses may be restricted to
those larger studies.
Data synthesis
Where studies are sufficiently similar in terms of population, in-
tervention and comparisons, pooled estimates of effectiveness will
be generated for similar outcomes, as appropriate. This will be
conducted by meta-analysing the data using a random-effects
model as the default method where I2 > 30 (see Assessment of
heterogeneity).
For analysis, studies will be grouped by intervention type. While
this will depend on what is found in included studies, this will
most likely be based on the point of delivery or the timing of the
intervention (in custody (i.e. pre-release), post-release, both pre-
and post-release components) and whether or not the intervention
is ’tailored’ or personalised for individual circumstances, charac-
teristics, needs, or a combination of these.
Within each intervention type, studies will be grouped by study
design with RCTs and cluster RCTs in one group, quasi-RCTs
and controlled before-and-after studies in a second group and in-
terrupted time series in a third group. Outcomes will be reported
in the review according to the primary and secondary review out-
comes and within those categories, will be grouped as follows: sub-
stance use, health-related quality of life, physical health, mental
health, health service utilisation, sexual risk behaviour and recidi-
vism.
Qualitative data will be used to provide context for the findings
and information about intervention implementation. Where ap-
propriate, this will be used to guide risk of bias assessment as well
as assessment of the intensity of interventions. If sufficient infor-
mation related to the implementation of interventions in included
studies is available, this will be tabulated separately in the review
alongside information about cost/resource requirements to assist
readers in their assessment of applicability and transferability.
For each study, we will capture whether or not outcomes
are reported by any of the socio-demographic characteristics
known to be important from an equity perspective based on the
PROGRESS-Plus framework. Where outcomes are reported by
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any of the PROGRESS-Plus factors, we will highlight narratively
whether or not the primary authors found differences in the im-
pact of interventions by those factors. Selected factors have been
nominated below for subgroup analyses (gender, racial/ethnic mi-
nority status).
The main findings of the review will be set out in a ’Summary
of findings’ table that will incorporate findings for the primary
review outcomes as well as the secondary review outcome, health
service utilisation (the hypothesised proximate outcome), along
with number of participants and studies. The number of studies
reporting at least one adverse outcome will also be reported in the
’Summary of findings’ table; however, due to expected heterogene-
ity in potential adverse outcomes, this will not be disaggregated
by specific adverse outcome type. The overall quality of the body
of evidence for primary outcomes will be summarised at the out-
come level according to the GRADE criteria: study limitations,
inconsistency, imprecision, indirectness and publication bias.
Subgroup analysis and investigation of heterogeneity
Subject to data availability, wewill conduct the following subgroup
analyses:
1. demographic characteristics: does the treatment effect differ
as a function of (a) age (< 25 years vs. ≥ 25 years), (b) gender
(male vs. female), or (c) racial/ethnic minority group status
(minority vs. not, recognising the limitations of aggregating
diverse cultural groups)?
2. sentencing status: does the treatment effect differ for those
released from pre-trial detention (remand) and those released
after a prison sentence?
3. tailoring of intervention: is the treatment effect different for
interventions delivered in a manualised (’one size fits all’) style
versus tailored to individual circumstances, characteristics, needs,
or a combination of these?
These subgroup analyses will be applied to our two primary out-
comes and one secondary outcome (health service utilisation) as
the hypothesised ’proximate’ outcome. Each analysis is comparing
only two subgroups (based on derived binary exposure variables),
so we will examine differences between subgroups by inspection of
the CIs for the summary estimates in the two groups, where non-
overlapping CIs will indicate a statistically significant difference
between the summary estimate in each group.
Sensitivity analysis
Studies judged to be at high risk of bias will be excluded in a sen-
sitivity analysis. Studies where participation in the intervention
was mandatory (vs. voluntary) will be excluded in a second sensi-
tivity analysis. If meta-analyses have been conducted and we are
concerned about small study effects, we will compare the fixed-
and random-effects estimate of the intervention effect in a third
sensitivity analysis. All sensitivity analyses will be conducted on
our two primary outcomes and one secondary outcome, health
service utilisation, as the hypothesis ’proximate’ outcome.
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